ABSTRACT
End-of-treatment (EoT) PET/CT is used as a guide to omit radiotherapy (RT) patients with primary mediastinal large B-cell lymphoma (PMBCL). We present the mature and extended results of a retrospective study evaluating the prognostic significance of EoT-PET/CT after adequate response to R-CHOP. Among 231 consecutive PMLBCL patients, 182 underwent EoT-PET/CT and were evaluated according to the Deauville 5-point scale (D5PS) criteria. Freedom from progression (FFP) was measured from the time of PET/CT examination. Among 182 patients, 72 (40%) had D5PS score 1 (D5PSS-1), 33 (18%) had 2, 28 (15%) had 3, 29 (16%) had 4, and 20 (11%) had 5. The 5-year FFP was 97, 94, 92, 82, and 44% for D5PSS-1, D5PSS-2, D5PSS-3, D5PSS-4, and D5PSS-5, respectively. Among 105 patients with unequivocally negative PET/CT (D5PSS-1/D5PSS-2), 49 (47%) received RT (median dose 3420 cGy) and 56 (53%) did not with relapses in 0/49 vs. 4/56 patients (2 mediastinum and 2 isolated CNS relapses).The 5-year FFP for those who received RT or not was 100% versus 96%, when isolated CNS relapses were censored (p = 0.159). Among D5PSS-3 patients (27/28 irradiated-median dose 3600 cGy), the 5-year FFP was 92%. The 5-year FFP for D5PSS-4 and D5PSS-5 was 82 and 44%; 44/49 patients received RT (median dose 4000 and 4400 cGy for D5PSS-4 and D5PSS-5). Our study supports the omission of RT in a sizeable fraction of PET/CT-negative patients and definitely discourages salvage chemotherapy and ASCT in patients with PMLBCL who conventionally respond to R-CHOP, solely based on PET/CT positivity in the absence of documented progressive or multifocal disease. The persistence of positive PET/CT with D5PSS < 5 after consolidative RT should not trigger the initiation of further salvage chemotherapy in the absence of conventionally defined PD.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Lymphoma, Large B-Cell, Diffuse/drug therapy , Lymphoma, Large B-Cell, Diffuse/radiotherapy , Mediastinal Neoplasms/drug therapy , Mediastinal Neoplasms/radiotherapy , Adolescent , Adult , Aged , Cyclophosphamide/therapeutic use , Doxorubicin/therapeutic use , Female , Humans , Lymphoma, Large B-Cell, Diffuse/diagnostic imaging , Male , Mediastinal Neoplasms/diagnostic imaging , Middle Aged , Positron Emission Tomography Computed Tomography , Prednisone/therapeutic use , Retrospective Studies , Rituximab/therapeutic use , Treatment Outcome , Vincristine/therapeutic use , Young AdultABSTRACT
BACKGROUND/AIM: The aim of the study was to prospectively compare I-131 postablation Whole Body scan (WBS) and Single Photon Emission Computerized Tomography/Computerized Tomography (SPECT/CT) scan on thyroid cancer patients. PATIENTS AND METHODS: Overall, 58 patients with papillary thyroid carcinoma were submitted to total thyroidectomy and I-131 remnant ablation. Post-ablation WBS and SPECT/CT scans performed on the same day were compared. Results of SPECT/CT were confirmed by neck and upper mediastinum ultrasound scan and on specific cases by a fully diagnostic CT scan, other tests and definitive histology acting as the gold standard. A total of 36/58 patients were followed-up for 5 years to detect relapse. RESULTS: Mac Nemar Chi square and Fisher's exact tests disclosed statistically significant differences between WBS and SPECT/CT scan, concerning cervical lymphadenopathy detection (p=0.031) and relapse prediction by NM stage (p=0.033), respectively; SPECT/CT was more accurate in both comparisons. CONCLUSION: In papillary thyroid carcinoma I-131 post-ablation SPECT/CT scan detects cervical lymphadenopathy and predicts relapse by NM stage more accurately than WBS.
Subject(s)
Iodine Radioisotopes , Thyroid Cancer, Papillary/diagnosis , Tomography, Emission-Computed, Single-Photon , Tomography, X-Ray Computed , Whole Body Imaging , Adult , Aged , Aged, 80 and over , Biomarkers , Female , Humans , Male , Middle Aged , Recurrence , Sensitivity and Specificity , Thyroid Cancer, Papillary/therapy , Tomography, Emission-Computed, Single-Photon/methods , Tomography, Emission-Computed, Single-Photon/standards , Tomography, X-Ray Computed/methods , Tomography, X-Ray Computed/standards , Whole Body Imaging/methods , Whole Body Imaging/standardsABSTRACT
18F-fluorothymidine (18F-FLT) is a radiolabeled thymidine analog that has been reported to help monitor tumor proliferation and has been studied in primary brain tumors; however, knowledge about 18F-FLT positron emission tomography/computed tomography (PET/CT) in metastatic brain lesions is limited. The purpose of this study is to evaluate the performance of 18F-FLT-PET/CT in metastatic brain lesions. A total of 20 PET/CT examinations (33 lesions) were included in the study. Semiquantitative analysis was performed: standard uptake value (SUV) with the utilization of SUVmax, tumor-to-background ratio (T/B), SUVpeak, SUV1cm³, SUV0.5cm³, SUV50%, SUV75%, PV50% (volume × SUV50%), and PV75% (volume × SUV75%) were calculated. Sensitivity, specificity, and accuracy for each parameter were calculated. Optimal cutoff values for each parameter were obtained. Using a receiver operating characteristic (ROC) curve analysis, the optimal cutoff values of SUVmax, T/B, and SUVpeak for discriminating active from non-active lesions were found to be 0.615, 4.21, and 0.425, respectively. In an ROC curve analysis, the area under the curve (AUC) is higher for SUVmax (p-value 0.017) compared to the rest of the parameters, while using optimal cutoff T/B shows the highest sensitivity and accuracy. PVs (proliferation × volumes) did not show any significance in discriminating positive from negative lesions. 18F-FLT-PET/CT can detect active metastatic brain lesions and may be used as a complementary tool. Further investigation should be performed.
ABSTRACT
AIM: To examine the real-life impact of baseline positron-emission tomography/computed tomography (PET/CT) in Hodgkin lymphoma (HL). PATIENTS AND METHODS: A total of 162 consecutive patients with HL were retrospectively studied. RESULTS: Disease was up-staged in 26 patients (16%) and down-staged in 9 (6%). However, treatment strategy was modified in only 10 patients (6% of total). Involved field radiotherapy was delineated according to PET/CT in 36/66 patients (59%). These treatment modifications did not significantly affect outcome. Moreover, three potent prognostic parameters were identified: the number of involved sites, maximum standardized uptake value (SUVmax), and the product of SUVmax and maximal largest lesion diameter, as a surrogate of total lesion glycolysis. All three significantly correlated with 5-year freedom from disease progression p=0.004, p=0.009 and p=0.04, respectively). CONCLUSION: Baseline PET/CT findings may lead to treatment modification in <15% of patients with HL without a significant impact on outcome. Certain PET/CT parameters have potent prognostic significance.
Subject(s)
Hodgkin Disease/diagnostic imaging , Neoplasm Staging/methods , Positron Emission Tomography Computed Tomography , Adolescent , Adult , Aged , Aged, 80 and over , Disease-Free Survival , Female , Hodgkin Disease/mortality , Hodgkin Disease/therapy , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Predictive Value of Tests , Reproducibility of Results , Retrospective Studies , Time Factors , Treatment Outcome , Young AdultABSTRACT
The contribution of positron emission tomography/computed tomography (PET/CT) with 18F-fludeoxyglucose (FDG) in evaluating ovarian cancer recurrence even after a prolonged disease-free interval, and in therapy response is well-described. Calcifications observed in CT, although usually attributed to benign conditions, may actually represent active disease. Such an example of calcified formations is psammoma bodies. We present a case of 56-y. o. patient with ovarian cancer relapse at the supraclavicular area 18 years after complete response and disease-free interval. The patient received chemotherapy and underwent 18F-FDG-PET/CT for the evaluation of treatment response. Both CT corrected and uncorrected PET images showed hypermetabolism in the massively calcified lymph nodes in the neck, mediastinum, axilla and abdomen, indicative of active residual disease.
ABSTRACT
OBJECTIVE: Augmented brown adipose tissue (BAT) mass and activity lead to higher basic metabolic rate which is beneficial against obesity. Our aim was to investigate whether habitual (i.e. usual weekly participation) physical activity is linked with BAT activity and mass in humans, in a group of patients undergoing (18) F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) scanning. DESIGN: Cross-sectional study. PATIENTS: Forty patients with cancer [26 male; 14 female; age 52·7 ± 17·5; body mass index (BMI) 26·4 ± 4·5]. MEASUREMENTS: Patients completed the 'usual week' form of the International Physical Activity Questionnaire and underwent assessment of BAT activity/mass via (18) F-fluorodeoxyglucose PET/CT. RESULTS: We detected a significant association between habitual physical activity (METs-minute/week) and BAT activity [normalized by body weight (BW) (τ = 0·28, P = 0·02), body surface area (BSA) (τ = 0·29, P = 0·02) and lean body mass (LBM) (τ = 0·38, P = 0·002)]. We also found a significant negative relationship between BMI and BAT activity [normalized by BW (τ = -0·30, P = 0·006), BSA (τ = -0·31, P = 0·004) and LBM (τ = -0·45, P = 0·001)] as well as a significant negative relationship between age and BAT activity [normalized by LBM (τ = -0·28, P = 0·01)]. The results also indicate significant differences between low/moderate/high levels of habitual physical activity and BAT activity (P < 0·05). Moreover, BAT activity was different across the BMI categories (normal/overweight/obese) in both sexes (P < 0·05). Finally, BAT activity was greater in women than in men (P < 0·05). CONCLUSIONS: Increased participation in habitual physical activity is associated with higher BAT activity. Moreover, individuals with normal BMI demonstrate higher BAT activity compared to overweight and obese individuals. Finally, age is inversely linked with BAT activity, while women demonstrate higher BAT activity than men.
Subject(s)
Adipose Tissue, Brown/metabolism , Body Mass Index , Life Style , Motor Activity/physiology , Adipose Tissue, Brown/anatomy & histology , Adult , Aged , Aged, 80 and over , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Neoplasms , Positron-Emission Tomography , Tomography, X-Ray Computed , Young AdultABSTRACT
Three patients, 2 women and 1 man, with primary (AL) amyloidosis without congestive heart failure are described; all 3 patients presented reduced I-123 metaiodobenzylguanidine (MIBG) myocardial uptake suggesting marked cardiac sympathetic denervation. This is the first time myocardial adrenergic denervation is described in patients with AL amyloidosis without evidence of congestive heart failure; the observed denervation could be implicated in the pathogenesis of cardiac conduction disturbances which are common in this disease.